Last reviewed · How we verify
NCT05502432
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
NA trial testing Active repetitive transcranial magnetic stimulation in Spinocerebellar Ataxia Type 3 in 39 participants. Completed in 30 October 2019.
1 October 2019
Quick facts
| Lead sponsor | Ning Wang, MD., PhD. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 17 December 2018 |
| Primary completion | 1 October 2019 |
| Estimated completion | 30 October 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Active repetitive transcranial magnetic stimulation
- Sham repetitive transcranial magnetic stimulation
Conditions studied
- Spinocerebellar Ataxia Type 3 — all drugs for Spinocerebellar Ataxia Type 3 →
Sponsor
Ning Wang, MD., PhD.
Who can join
Adults 20 to 80, any sex, with Spinocerebellar Ataxia Type 3. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide.Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy used to treat depression and cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a 15 day treatment with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) can improve symptoms (motor symptoms and non-motor symptoms) in patients with MJD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05502432
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active repetitive transcranial magnetic stimulation
Trials testing the same drug.
- NCT05295498 — Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain · NA · recruiting
- NCT04720196 — Analgesic Effect of rTMS in Vasculitic Neuropathy · NA · terminated
- NCT02853032 — Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related Post-Traumatic Stress · NA · completed
Other recruiting trials for Spinocerebellar Ataxia Type 3
Currently open trials in the same condition.
- NCT05822908 — A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD · Phase 1, PHASE2 · recruiting
Other Ning Wang, MD., PhD. trials
Trials by the same sponsor.
- NCT04637074 — A Cohort Study on Thrombectomy for Stroke · unknown
- NCT04629872 — Fingolimod in Endovascular Treatment of Ischemic Stroke · Phase 2 · unknown
- NCT04386018 — A Registered Cohort Study of Inflammatory Demyelination Disease · unknown
- NCT04303962 — Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome · unknown
- NCT04010188 — A Registered Cohort Study on Charcot-Marie-Tooth Disease · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05502432 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ning Wang, MD., PhD.
- Last refreshed: 16 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05502432.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing